SCHEMBL5637192

SCHEMBL5637192

CC1(CSc2nccn2-c2ccccc2)CCC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.56
CYP1A2 P05177 5/20 0.56
CYP3A4 P08684 5/20 0.56
CYP2D6 P10635 5/20 0.56
CYP2C9 P11712 5/20 0.56
CYP2C19 P33261 5/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
RAB9A P51151 2/20 0.55
NPC1 O15118 1/20 0.55
ALOX15B O15296 3/20 0.54
GAA P10253 2/20 0.54
ALDH1A1 P00352 4/20 0.48
POLB P06746 1/20 0.48
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
TP53 P04637 1/20 0.45
TSHR P16473 2/20 0.44
CTSK P43235 1/20 0.43
LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5637186 0.84 L3MBTL1 (0.55) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL4907411 0.82 CYP1A2 (0.52) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5637310 0.77 L3MBTL1 (0.44) L3MBTL1SMN1; SMN2RAB9ANPC1GAA
SCHEMBL24945135 0.72 L3MBTL1 (1.00) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL24945138 0.71 CYP1A2 (1.00) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL24944906 0.70 CYP1A2 (1.00) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL11484429 0.70 L3MBTL1 (0.62) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL5636836 0.68 HSD17B10 (0.37) SMN1; SMN2RAB9ANPC1ALDH1A1KMT2A
SCHEMBL9168747 0.68 CYP1A2 (0.68) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL25547776 0.68 ALDH1A1 (0.64) L3MBTL1CYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7282512-B2 Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-10-16 US claimed
US-20050054819-A1 Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors SMITHKLINE BEECHAM CORPORATION 2005-03-10 US claimed
US-7282512-B2 Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2007-10-16 US disclosed
US-20050054819-A1 Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors SMITHKLINE BEECHAM CORPORATION 2005-03-10 US disclosed
EP-1465862-A1 CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS SmithKline Beecham Corporation (US) 2004-10-13 EP disclosed
WO-2003062192-A1 CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054819-A1 Cycloalkyl ketoamides derivatives useful as cathepsin k inhibitors CTSK, CTSS, CTSE L3MBTL1 2634/4885CYP1A2 2920/4885CYP3A4 3318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.